Amarin Reaffirms the Proven, Guideline-Recommended Role of VASCEPA® (Icosapent Ethyl) in an Evolving Triglyceride Treatment Landscape
Amarin responded to the FDA approval of injectable APOC3 therapies for severe hypertriglyceridemia, asserting that VASCEPA remains a critical first-line option due to its established efficacy and lower cost. The company highlighted a significant cost differential, noting VASCEPA's annual wholesale acquisition cost is approximately $4,200 per patient compared to $40,000 for the new injectables.
Key figures
- Vascepa wac
- 4200
- Competitor wac
- 40000
- Cv risk reduction
- 25%
- Tg reduction shtg
- 33%
- Global prescriptions
- 30 million
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.